Special Investigation Of Genotropin Long Follow-Up For Patients With A Small For Gestational Age (SGA)
Information source: Pfizer
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Small for Gestational Age (SGA)
Intervention: Somatropin (Drug)
Phase: N/A
Status: Active, not recruiting
Sponsored by: Pfizer Official(s) and/or principal investigator(s): Pfizer CT.gov Call Center, Study Director, Affiliation: Pfizer
Summary
The objective of this surveillance is to collect Safety and Effectiveness information for
Long term Use of Somatropin for Patients with a Small for Gestational Age (SGA).
Clinical Details
Official title: Special Investigation For Genotropin(Sga Long Follow-up)
Study design: Observational Model: Cohort, Time Perspective: Retrospective
Primary outcome: Change in growth rate SD score for calendar ageChange in height SD score for calendar age
Secondary outcome: Final height
Detailed description:
All the patients whom an investigator prescribes Genotropin should be registered
consecutively until the number of subjects reaches target number in order to extract
patients enrolled into the investigation at random.
Eligibility
Minimum age: N/A.
Maximum age: 20 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- A patient who was administered Somatropin (Genotropin).
Exclusion Criteria:
- N/A.
Locations and Contacts
Additional Information
To obtain contact information for a study center near you, click here.
Starting date: September 2013
Last updated: July 30, 2015
|